Literature DB >> 8227863

Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies.

R M Naclerio1, N F Adkinson, P S Creticos, F M Baroody, R G Hamilton, P S Norman.   

Abstract

We performed two seasonal studies to evaluate the effect of continuous treatment with intranasal steroids, beginning approximately 1 week before the appearance of ragweed pollen, on the level of ragweed-specific IgE antibodies in serum. In both studies the control groups showed the anticipated rise in ragweed-specific IgE antibodies after the ragweed season. In the first study, employing aqueous beclomethasone dipropionate (168 micrograms twice daily), no rise occurred in serum ragweed IgE after seasonal exposure and the level actually decreased in eight of 12 treated subjects. In the second study, with triamcinolone acetonide (220 micrograms twice daily), the expected rise in ragweed IgE antibody was also reduced, although less dramatically, probably as a result of the lower potency of the dose delivered. Our studies not only support the benefits of intranasal steroids in the treatment of seasonal allergic rhinitis but also suggest that specific IgE production may be down-regulated by their continuous use, which may alter the subsequent clinical course of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227863     DOI: 10.1016/0091-6749(93)90015-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Intranasal corticosteroids for allergic rhinitis: superior relief?

Authors:  L P Nielsen; N Mygind; R Dahl
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

Authors:  J Corne; R Djukanovic; L Thomas; J Warner; L Botta; B Grandordy; D Gygax; C Heusser; F Patalano; W Richardson; E Kilchherr; T Staehelin; F Davis; W Gordon; L Sun; R Liou; G Wang; T W Chang; S Holgate
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

3.  Effectiveness of quercetin in an experimental rat model of allergic rhinitis.

Authors:  Mustafa Sagit; Halil Polat; Seren Gulsen Gurgen; Elife Berk; Sabri Guler; Mehmet Yasar
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-10       Impact factor: 2.503

Review 4.  Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis.

Authors:  W Jeal; D Faulds
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 5.  Intranasal steroids in the treatment of allergy-induced rhinorrhea.

Authors:  Robert A Nathan
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

6.  Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism.

Authors:  Atsushi Kato; Ai Q Truong-Tran; Alan L Scott; Kenji Matsumoto; Robert P Schleimer
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

Review 7.  Evidence-based treatment of allergic rhinitis.

Authors:  R Pawankar; W Fokkens
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.806

Review 8.  Pharmacological management of nasal polyposis.

Authors:  Claus Bachert; Jean-Baptiste Watelet; Philippe Gevaert; Paul Van Cauwenberge
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Hydrocortisone enhances total IgE levels--but not the synthesis of allergen-specific IgE--in a monocyte-dependent manner.

Authors:  B Bohle; M Willheim; K Baier; B Stadler; S Spitzauer; O Scheiner; D Kraft; C Ebner
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

10.  Effects of nasal corticosteroids on boosts of systemic allergen-specific IgE production induced by nasal allergen exposure.

Authors:  Cornelia Egger; Christian Lupinek; Robin Ristl; Patrick Lemell; Friedrich Horak; Petra Zieglmayer; Susanne Spitzauer; Rudolf Valenta; Verena Niederberger
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.